SeekingAlpha · Jul 30, 2026
HUTCHMED (China) Limited (HCM) Q2 2026 Earnings Call Transcript
HUTCHMED (China) Limited (HCM) Q2 2026 Earnings Call July 30, 2026 8:00 AM EDTCompany ParticipantsDavid Ng - Head of Investor Relations & Capital...
NASDAQ · HCM
HUTCHMED (China) Limited American Depositary Shares
Healthcare · Drug Manufacturers - Specialty & Generic
$12.20
Up+$0.04 (+0.33%)
Updated Aug 16, 2026, 8:21 AM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.39B
- P/E ratio
- 5.13
- Dividend yield
- 0.00%
- 52-week range
- $9.77 – $18.30
- Volume
- 13.09K
- Avg. volume
- 38.74K
Price performance
HCM price history
1M range · 20 trading sessions · Daily adjusted prices
HCM closed at $12.20 after 20 trading sessions, up 7.77% for the selected period.
- Last close
- $12.20
- Period change
- +7.77%
- Period low
- $10.77
- Period high
- $12.55
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $12.19 | $12.27 | $12.08 | $12.20 | 13.09K |
| Aug 13, 2026 | $12.07 | $12.23 | $12.00 | $12.16 | 77.12K |
| Aug 12, 2026 | $12.36 | $12.40 | $12.21 | $12.25 | 34.29K |
| Aug 11, 2026 | $12.55 | $12.55 | $12.40 | $12.47 | 16.92K |
| Aug 10, 2026 | $12.56 | $12.67 | $12.44 | $12.55 | 44.03K |
| Aug 7, 2026 | $12.09 | $12.56 | $12.09 | $12.51 | 43.35K |
| Aug 6, 2026 | $11.54 | $11.88 | $11.54 | $11.83 | 31.53K |
| Aug 5, 2026 | $11.57 | $11.59 | $11.50 | $11.55 | 21.13K |
| Aug 4, 2026 | $11.62 | $11.635 | $11.54 | $11.57 | 12.66K |
| Aug 3, 2026 | $11.38 | $11.61 | $11.275 | $11.55 | 82.1K |
| Jul 31, 2026 | $11.00 | $11.13 | $10.905 | $11.13 | 38.56K |
| Jul 30, 2026 | $11.10 | $11.21 | $10.62 | $10.77 | 59.68K |
| Jul 29, 2026 | $11.36 | $11.60 | $11.30 | $11.39 | 43.43K |
| Jul 28, 2026 | $11.04 | $11.24 | $11.04 | $11.20 | 27.73K |
| Jul 27, 2026 | $11.06 | $11.22 | $11.06 | $11.12 | 40.12K |
| Jul 24, 2026 | $10.96 | $11.12 | $10.91 | $11.01 | 50.65K |
| Jul 23, 2026 | $11.02 | $11.07 | $10.9305 | $10.96 | 45.78K |
| Jul 22, 2026 | $11.39 | $11.405 | $11.12 | $11.12 | 75.09K |
| Jul 21, 2026 | $11.34 | $11.36 | $11.16 | $11.18 | 33.25K |
| Jul 20, 2026 | $11.25 | $11.33 | $11.11 | $11.32 | 78.78K |
Latest HCM news
The latest Smart Investors Daily articles mentioning HCM.
Stock researchCompany · Overview
HCM research
Overview
Company profile and research snapshot.
Company profile
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $17.50
- Implied upside
- —
- Analysts
- 27
News briefing
No generated briefing is available yet.
SeekingAlpha · Jul 30, 2026
HUTCHMED (China) Limited 2026 Q2 - Results - Earnings Call Presentation
2026-07-30. The following slide deck was published by HUTCHMED (China) Limited in conjunction with their 2026 Q2 earnings call.
Benzinga · Jul 30, 2026
HUTCHMED (China) H1 EPS $0.09 Down From $2.61 YoY, Sales $278.287M Up From $277.677M YoY
HUTCHMED (China) (NASDAQ:HCM) reported quarterly earnings of $0.09 per share. This is a 96.55 percent decrease over earnings of $2.61 per share from the same period last year. The company reported $278.287 million in
Benzinga · Jul 23, 2026
Goldman Sachs Maintains Neutral on HUTCHMED (China), Lowers Price Target to $14
Goldman Sachs analyst Paul Choi maintains HUTCHMED (China) (NASDAQ:HCM) with a Neutral and lowers the price target from $16 to $14.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
